Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16808524 | 1.00 | CYP3A4 (0.40) | CYP3A4MAPK1HCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL18802267 | 1.00 | CYP3A4 (0.40) | CYP3A4MAPK1HCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL17093290 | 1.00 | CYP3A4 (0.40) | CYP3A4MAPK1HCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL18801954 | 0.86 | CYP3A4 (0.42) | CYP3A4MAPK1HCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL14626066 | 0.86 | CYP3A4 (0.42) | CYP3A4MAPK1HCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL16808485 | 0.86 | CYP3A4 (0.42) | CYP3A4MAPK1HCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL5331015 | 0.86 | CYP3A4 (0.42) | CYP3A4MAPK1HCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL16808428 | 0.81 | TP53 (0.36) | CYP3A4MAPK1HCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL16808575 | 0.81 | TP53 (0.36) | CYP3A4MAPK1HCRTR2HCRTR1ALDH1A1 | |
| SCHEMBL18176799 | 0.80 | CYP3A4 (0.39) | CYP3A4MAPK1HCRTR2HCRTR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221783-B2 | Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-12-29 | — | — | US | disclosed |
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266848-A1 | PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME | MYLK, MUSK, MYLK2 | CYP3A4 1619/4885MAPK1 3470/4885HCRTR2 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.